Cargando…
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy
OBJECTIVE: To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management. METHODS: A previously developed cost effectiveness model was...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316918/ https://www.ncbi.nlm.nih.gov/pubmed/25227704 http://dx.doi.org/10.1136/heartjnl-2014-305864 |
_version_ | 1782355639887986688 |
---|---|
author | Janzon, M James, S Cannon, C P Storey, R F Mellström, C Nicolau, J C Wallentin, L Henriksson, M |
author_facet | Janzon, M James, S Cannon, C P Storey, R F Mellström, C Nicolau, J C Wallentin, L Henriksson, M |
author_sort | Janzon, M |
collection | PubMed |
description | OBJECTIVE: To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management. METHODS: A previously developed cost effectiveness model was used to estimate long-term costs and outcomes for patients scheduled for non-invasive management. Healthcare costs, event rates and health-related quality of life under treatment with either ticagrelor or clopidogrel over 12 months were estimated from the PLATO study. Long-term costs and health outcomes were estimated based on data from PLATO and published literature sources. To investigate the importance of different healthcare cost structures and life expectancy for the results, the analysis was carried out from the perspectives of the Swedish, UK, German and Brazilian public healthcare systems. RESULTS: Ticagrelor was associated with lifetime quality-adjusted life-year (QALY) gains of 0.17 in Sweden, 0.16 in the UK, 0.17 in Germany and 0.13 in Brazil compared with generic clopidogrel, with increased healthcare costs of €467, €551, €739 and €574, respectively. The cost per QALY gained with ticagrelor was €2747, €3395, €4419 and €4471 from a Swedish, UK, German and Brazilian public healthcare system perspective, respectively. Probabilistic sensitivity analyses indicated that the cost per QALY gained with ticagrelor was below conventional threshold values of cost effectiveness with a high probability. CONCLUSIONS: Treatment of patients with ACS scheduled for 12 months’ non-invasive management with ticagrelor is associated with a cost per QALY gained below conventional threshold values of cost effectiveness compared with generic clopidogrel. TRIAL REGISTRATION NUMBER: NCT000391872. |
format | Online Article Text |
id | pubmed-4316918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43169182015-02-11 Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy Janzon, M James, S Cannon, C P Storey, R F Mellström, C Nicolau, J C Wallentin, L Henriksson, M Heart Healthcare Delivery, Economics and Global Health OBJECTIVE: To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management. METHODS: A previously developed cost effectiveness model was used to estimate long-term costs and outcomes for patients scheduled for non-invasive management. Healthcare costs, event rates and health-related quality of life under treatment with either ticagrelor or clopidogrel over 12 months were estimated from the PLATO study. Long-term costs and health outcomes were estimated based on data from PLATO and published literature sources. To investigate the importance of different healthcare cost structures and life expectancy for the results, the analysis was carried out from the perspectives of the Swedish, UK, German and Brazilian public healthcare systems. RESULTS: Ticagrelor was associated with lifetime quality-adjusted life-year (QALY) gains of 0.17 in Sweden, 0.16 in the UK, 0.17 in Germany and 0.13 in Brazil compared with generic clopidogrel, with increased healthcare costs of €467, €551, €739 and €574, respectively. The cost per QALY gained with ticagrelor was €2747, €3395, €4419 and €4471 from a Swedish, UK, German and Brazilian public healthcare system perspective, respectively. Probabilistic sensitivity analyses indicated that the cost per QALY gained with ticagrelor was below conventional threshold values of cost effectiveness with a high probability. CONCLUSIONS: Treatment of patients with ACS scheduled for 12 months’ non-invasive management with ticagrelor is associated with a cost per QALY gained below conventional threshold values of cost effectiveness compared with generic clopidogrel. TRIAL REGISTRATION NUMBER: NCT000391872. BMJ Publishing Group 2015-01-15 2014-09-16 /pmc/articles/PMC4316918/ /pubmed/25227704 http://dx.doi.org/10.1136/heartjnl-2014-305864 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Healthcare Delivery, Economics and Global Health Janzon, M James, S Cannon, C P Storey, R F Mellström, C Nicolau, J C Wallentin, L Henriksson, M Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy |
title | Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy |
title_full | Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy |
title_fullStr | Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy |
title_full_unstemmed | Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy |
title_short | Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy |
title_sort | health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy |
topic | Healthcare Delivery, Economics and Global Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316918/ https://www.ncbi.nlm.nih.gov/pubmed/25227704 http://dx.doi.org/10.1136/heartjnl-2014-305864 |
work_keys_str_mv | AT janzonm healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy AT jamess healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy AT cannoncp healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy AT storeyrf healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy AT mellstromc healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy AT nicolaujc healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy AT wallentinl healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy AT henrikssonm healtheconomicanalysisofticagrelorinpatientswithacutecoronarysyndromesintendedfornoninvasivetherapy |